Shares of BioCryst Pharmaceuticals Inc. (BCRX) cratered over 71% on Monday, following disappointing results from a 12-week, three-arm, parallel cohort design trial of orally-administered Avoralstat in patients with hereditary angioedema.
Forex – financial instrument.Forex news
Shares of BioCryst Pharmaceuticals Inc. (BCRX) cratered over 71% on Monday, following disappointing results from a 12-week, three-arm, parallel cohort design trial of orally-administered Avoralstat in patients with hereditary angioedema.